Life Sciences
Medical devices company Owen Mumford achieves B Corp certification
The Woodstock based company was awarded B Corp certification after demonstrating strict compliance to the rigorous requirements of this globally-recognised mark.
Oxford biotech firm plans clinical trial for next-generation COVID-19 vaccine
The studies will allow the company to assess the ability of its next-generation vaccine to boost the immune response against current and potential future strains of COVID-19.
ATDBio establishes molecular diagnostics lab at The Oxford Science Park
The 745 sq ft molecular diagnostics research and quality control lab will support its customers in developing improved molecular diagnostics for COVID-19 and other pathogens.
Exscientia acquires personalised medicine AI pioneer Allcyte
The combination expands Exscientia’s capabilities by enabling high content evaluation of individual patient biology in primary tumour tissues rather than artificial cell lines or animal models.
DJS Antibodies moves to newly converted lab space at Wood Centre for Innovation
Biotech start-up, DJS Antibodies, is the second company to move into the newly converted class II laboratory space at The Oxford Trust’s Wood Centre for Innovation.
G7 health summit highlights Oxfordshire’s thriving life sciences sector
The arrival of G7 health ministers to Oxford on Thursday 03 June will shine a spotlight on Oxfordshire’s considerable achievements in the life sciences sector.
Revenue quadruples in Sensyne Health trading update for 2021
The company has reported robust financial performance in its 2021 unaudited revenues of at least £9.0 million compared to £2.1 million in the 2020 audited accounts.
Oxford Biomedica to increase production of AstraZeneca COVID-19 vaccine
AstraZeneca has committed to an increase in the number of batches required from Oxford Biomedica in the second half of 2021.
Oxford’s Vaccitech completes IPO on Nasdaq and raises $110.5m
The Oxford-based clinical-stage biopharmaceutical company that co-invented a COVID-19 vaccine is a spin-out from Oxford University’s Jenner Institute.
Sense raises $50m Series B funding for instrument-free product platform
The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare.
Oxford Endovascular raises $10m to develop its origami engineered medical device
The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study.
Exscientia announces first AI-designed immuno-oncology drug in clinical trials
The company’s technologies and drug-hunting expertise now responsible for the world’s first and second AI-designed drugs to enter Phase I testing.
